Rudolf W. Van Olden
Basel, BS 4056, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G.
Journal: Molecular therapy. Advances
Published: September 19, 2025
Economic evaluation of next-generation sequencing technologies in pediatric patient groups with confirmed or possible rare diseases: A systematic literature review.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: April 11, 2025
Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics.
Journal: Molecular therapy. Methods & clinical development
Published: July 24, 2024
Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy.
Journal: Molecular therapy. Methods & clinical development
Published: March 07, 2023
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: September 29, 2021
Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec.
Journal: Molecular therapy. Methods & clinical development
Published: December 10, 2020
Corrigendum: Core competencies for pharmaceutical physicians and drug development scientists.
Journal: Frontiers in pharmacology
Published: November 11, 2014
Core competencies for pharmaceutical physicians and drug development scientists.
Journal: Frontiers in pharmacology
Published: June 08, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026